African Journal of
Pharmacy and Pharmacology

  • Abbreviation: Afr. J. Pharm. Pharmacol.
  • Language: English
  • ISSN: 1996-0816
  • DOI: 10.5897/AJPP
  • Start Year: 2007
  • Published Articles: 2285

Full Length Research Paper

Potency and immunogenicity of bacillus calmette guerin (BCG) vaccines used in routine immunization programme in South-East, Nigeria

Oli, A. N*.
  • Oli, A. N*.
  • Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Agulu, Anambra State, Nigeria.
  • Search for this author on:
  • Google Scholar
Agu, R. U.
  • Agu, R. U.
  • Biopharmaceutics and Drug Delivery Laboratory, College of Pharmacy, 5968 College Street, PO Box 15000, Dalhousie University, B3H 4R2, Halifax, NS, Canada.
  • Search for this author on:
  • Google Scholar
Nnadozie, O. J.
  • Nnadozie, O. J.
  • Department of Chemical Pathology, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria.
  • Search for this author on:
  • Google Scholar
Onah, C. E.
  • Onah, C. E.
  • Department of Chemical Pathology, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria.
  • Search for this author on:
  • Google Scholar
Okeke, I. J.
  • Okeke, I. J.
  • Bichan Pharmaceutical Ltd, # 208 Ziks Avenue, Awka, Anambra State, Nigeria.
  • Search for this author on:
  • Google Scholar
Esimone, C. O.
  • Esimone, C. O.
  • Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Agulu, Anambra State, Nigeria.
  • Search for this author on:
  • Google Scholar


  •  Received: 12 October 2014
  •  Accepted: 03 December 2014
  •  Published: 22 December 2014

References

Babaniyi OA (1990). A 10-year review of morbidity from childhood preventable diseases in Nigeria: how successful is the expanded programme on immunization (EPI)? An update. J. Trop. Paediatr. 36:306-313.
Crossref
 
Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F (1994). Efficacy of BCG vaccine in the prevention of Tuberculosis. Meta analysis of the published literature. JAMA 271(9):698-702.
Crossref
 
European Pharmacopoeia. (2007). Directorate for the Quality of Medicines of the Council of Europe (5th Edition. ed.). Strasbourg, France: European Council.
 
Fine PE, Carneiro IA, Milstien JB, Clements CJ (1999). Issues relating to the use of BCG in immunization programmes. A discussion document. Geneva: World Health Organization. P 45.
 
Gie RP, Beyers N, Enarson D (2009). Epidemiology of childhood tuberculosis. In: Schaaf S, Zumia A, editors. Tuberculosis: A comprehensive clinical reference. Philadelphia: Saunders Elesevier.
Crossref
 
Hanekom W (2005). The Immune Response to BCG Vaccination of Newborns. Ann. NY Acad. Sci. 1062:69-78.
Crossref
 
Ho MM, Corbel MJ, Knezevic I, Roumiantzeff M (2005). Report on a WHO consultation on the characterization of BCG vaccines. WHO, Geneva, Switzerland 8-9 Dec 2004.
 
Ho MM, Markey K, Rigsby P, Hockley J, Corbel MJ (2011). Report of an International collaborative study to establish the first WHO reference reagents for BCG vaccines of three different sub-strains. Vaccine 29(3):512-8.
Crossref
 
Ho MM, Markey K, Rigsby P, Jensen SE, Gairola S, Seki M, Castello-Branco LR, López-Vidal Y, Knezevic I, Corbel MJ (2008). Report of an international collaborative study to establish the suitability of using modified ATP assay for viable count of BCG vaccine. Vaccine 26(36):4754-7.
Crossref
 
Indian Academy of Pediatrics (1990). Cold chain. In: Desai AB, Shah RC, Dutta A, Parthsarthy A, Mittal SK, Agarwal V et al. (eds.), Immunization programme in India – Need for a change. Mumbai; Indian Academy of Pediatrics; 1990. pp. 8-9, 48-50.
 
Indian Academy of Pediatrics. The Cold Chain (2001). In: Parthsarthy A, Dutta AK, Bhave S (eds.), IAP Guidebook on Immunization, 2nd edition. Mumbai: Indian Academy of Pediatrics. pp. 53-55.
 
Jensen SE, Hubrechts P, Klein BM, Haslov KR (2008). Development and validation of an ATP method for rapid estimation of viable units in lyophilized BCG Danish 1331 vaccine. Biologicals 36(5):308-14.
Crossref
 
Kairo SK, Bedwell J, Tyler PC, Carter A, Corbel MJ (1999). Development of a tetrazolium salt assay for rapid determination of viability of BCG vaccines. Vaccine 17(19):2423-8.
Crossref
 
Kaufmann SHE (1993). Immunity to intracellular bacteria. In Paul WE (ed.), Fundamental immunology, 3rd ed. Raven Press, New York. pp. 1251-1286.
 
Lagranderie MRR, Balazuc Anne-Marie, Deriaud E, Leclerc CD, Gheorghiu M (1996). Comparison of Immune Responses of Mice Immunized with Five Different Mycobacterium bovis BCG Vaccine Strains. Infect. Immun. pp. 64:1-9.
 
Lu M, Xia ZY, Bao L (2013). Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy. Cell Immunol. 285(1-2):111-7.
Crossref
 
Lu M, Xia ZY, Bao L (2014). A Mycobacterium bovis BCG-Naked DNA Prime-Boost Vaccination Strategy Induced CD4 and CD8+ T-Cell Response against Mycobacterium tuberculosis Immunogens. J. Immunol. Res. 2014:395626.
Crossref
 
Mrudula K, Kamlesh R (2003). Thermostability of Vaccines. Indian Pediatr. 40:311-319.
 
Nitin S (2013). BCG vaccine: Storage, Preparation, Dosing, Efficacy, Complications. http://www.pediatriconcall.com/fordoctor/Diseases_a_z/article.aspx?artid=386.
 
Odujinrin OM, Ogunmekan DA (1992). Assessment of post vaccination tuberculin sensitivity in Lagos-Nigeria. Eur. J. Epidemiol. 8:128-131.
Pubmed
 
Orogade AA, Ahmed P, Onazi SO, Abubakar U, Isa H (2013). BCG status in children with tuberculosis: A multicenter study in Northern Nigeria. J. Med. Trop. 15:126-130.
 
Parra M, Yang AL, Lim J, Kolibab K, Derrick S, Cadieux N, Perera LP, Jacobs WR, Brennan M, Morris SL (2009). Development of a murine Mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis. Clin. Vaccine Immunol. 16(7):1025-32.
Crossref
 
Petricevich VL, Ueda C, Alves RC, da Silva MA, Moreno C, Melo AR, Dias da Silva W (2001). A single strain of Mycobacterium bovis bacillus Calmette-Guérin (BCG) grown in two different media evokes distinct humoral immune responses in mice. Braz. J. Med. Biol. Res. 34(1):81-92.
Crossref
 
World Health Organization (2006a). State of the art of new vaccine research and development. Geneva, (WHO/IVB/06.01; http://whqlibdoc.who.int/hq/2006/WHO_IVB_06.01_eng.pdf.
 
World Health Organization (WHO) (2006b). Temperature Sensitivity of vaccines; Immunization, Vaccines and Biologicals. Geneva, Switzerland: World Health Organization.
 
British Pharmacopoeia (2011). Immunological Products: Vaccines (Vol. IV). The Royal Pharmaceutical Society of Great Britain London, Britain. United Kingdom: British Press.
 
World Health Organization (WHO) (2012). Global tuberculosis control. WHO report. Geneva. World Health Organization.
 
World Health Organization (WHO) (2013). WHO Expert Committee on Biological Standardization. World Health Organization Technical Report Series. No. 977.
 
World Health Organization Expert Committee on Biological Standardization (1987). Requirements for freeze-dried BCG vaccine. World Health Organization Technical Report Series. 745:60-92.

 

Copyright © 2024 Author(s) retain the copyright of this article.

This article is published under the terms of the Creative Commons Attribution License 4.0

Back to Vol. 8 No. 47
Back to articles
SUBSCRIBE TO RSS
SUBMIT MANUSCRIPT
CONFERENCES